Search
Peginterferon beta-1a
go.drugbank.com/drugs/DB09122ApprovedInvestigationalSymptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. … It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021.
Isavuconazonium
go.drugbank.com/drugs/DB06636ApprovedInvestigationalIsavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis … , marketed by Astellas under the brand Cresemba.
Nitrous acid
go.drugbank.com/drugs/DB09112ApprovedInvestigationalNitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. … It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.
Levoleucovorin
go.drugbank.com/drugs/DB11596ApprovedInvestigationalIn vitro, the levo-isomer has been shown to be rapidly converted to the biologically available methyl-tetrahydrofolate form while the dextro form is slowly excreted by the kidneys. … However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF).
Synonyms: N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acidProguanil
go.drugbank.com/drugs/DB01131ApprovedIt does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. … Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells.
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnIt exerts its antiviral action by preventing RNA replication and virion assembly via binding to NS5A, a nonstructural phosphoprotein encoded by HCV. … Daclatasvir is shown to target both the cis- and trans-acting functions of NS5A and disrupts the function of new HCV replication complexes by modulating the NS5A phosphorylation status [A19640].
Cocoa butter
go.drugbank.com/drugs/DB11086ApprovedFat cocoa solids, including cocoa butter, have lower phenolic content than non-fat cocoa solids but may contain some polyphenols of different structures of flavonoids with antioxidant properties [A33041 … It is a rich source of monounsaturated and saturated fatty acids [A33040] that mainly contains approximately 33% [DB04224], 25% [DB03796], and 33% [DB03193] [A20409] but does not contain caffeine or theobromine
Denosumab
go.drugbank.com/drugs/DB06643ApprovedInvestigational[A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. … It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk
Halofantrine
go.drugbank.com/drugs/DB01218ApprovedWithdrawnIt appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. … Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
Bromfenac
go.drugbank.com/drugs/DB00963ApprovedWithdrawnNon-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239]
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic